Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
Working Life
The changing shape of pharma workplaces
As a number of pharmacos open new premises, we ask how changing the physical work environment affects company staff and culture.
Approvals Action
Teva responds to generic threat
Last week generics maker Aspen registered a competitor for Teva's wakefulness drug Modavigil. Now the Israel-based major has struck back with a new product.
Special Report
Novartis MD: Time to embrace change
He has taken the helm at a time when many in the industry are concerned for the future but Novartis head Brian Gladsden says it is time to move forward, rebuild relationships with stakeholders and embrace change.
Open Forum
Time to get subjective about drugs
The highly objective approach to determining the effectiveness of drugs embodied in clinical trials comes under question from an Australian doctor and mathematician who says it may rule out useful treatments unnecessarily.
Pipeline Monitor
Regulators in a generous mood
The FDA and the EMA have been busy approving and recommending new cancer, HIV and heart failure drugs.